Empagliflozin in patients with chronic kidney disease

<p><strong>Background</strong></p> The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range o...

Description complète

Détails bibliographiques
Auteurs principaux:	Herrington, WG, Staplin, N, Green, JB, Hauske, SJ, Emberson, J, Preiss, D, Judge, P, Mayne, K, Ng, S, Sammons, E, Zhu, D, Hill, M, Stevens, W, Wallendszus, K, Brenner, S, Cheung, AK, Liu, Z-H, Li, J, Hooi, LS, Wen Liu, Kadowaki, T, Nangaku, M, Levin, A, Cherney, D, Maggioni, AP, Pontremoli, R, Deo, R, Goto, S, Rossello, X, Tuttle, KR, Steubl, D, Petrini, M, Massey, D, Eilbracht, J, Brueckmann, M, Landray, M, Baigent, C, Haynes, R
Autres auteurs:	EMPA-KIDNEY Collaborative Group
Format:	Journal article
Langue:	English
Publié:	Massachusetts Medical Society 2022

Empagliflozin in patients with chronic kidney disease

Documents similaires